Outlook Therapeutics, Inc. reported a net loss of $62.4 million for the fiscal year ended September 30, 2025, with $1.4 million in revenue. Sales of LYTENAVA™ in Germany and the UK contributed to revenue growth, despite a negative impact on gross profit due to increased reserves for short-dated inventory.

Expenses in fiscal 2025 were $4.6 million lower than the previous year, with reduced R&D costs offset by increased SG&A expenses for launching LYTENAVA™ in Europe. Cash and cash equivalents stood at $8.1 million as of September 30, 2025, excluding net proceeds from sales after that date.

Outlook Therapeutics is awaiting FDA approval for ONS-5010 by the PDUFA goal date of December 31, 2025. ONS-5010/LYTENAVA™ is an ophthalmic formulation of bevacizumab for wet AMD treatment, with approvals in Europe and ongoing approval processes in the US.

The company is focused on developing and commercializing ONS-5010/LYTENAVA™ to enhance bevacizumab treatment for retina diseases. With plans for market expansion and commercial activities in Europe and the US, Outlook Therapeutics aims to provide patients and physicians with access to approved ophthalmic formulations of bevacizumab.

Read more at GlobeNewswire: Outlook Therapeutics Reports Financial Results for Fiscal